Nuvectis Pharma, Inc. NVCT Finance Income
Finance Income at other companies
Other financials
Where this comes from
Reported directly by Nuvectis Pharma, Inc. in its filing.
Tagged under the XBRL concept nvct:FinanceIncome.
The official record: Nuvectis Pharma, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nuvectis Pharma, Inc.'s finance income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nuvectis Pharma, Inc.'s finance income?
- Nuvectis Pharma, Inc. (NVCT) reported finance income of $210K in Q1 2026.
- How has Nuvectis Pharma, Inc.'s finance income changed year-over-year?
- Nuvectis Pharma, Inc.'s finance income decreased by 11.0% year-over-year, from $236K to $210K.
- What is the long-term trend for Nuvectis Pharma, Inc.'s finance income?
- Over 4 years (2021 to 2025), Nuvectis Pharma, Inc.'s finance income has grown at a 310.2% compound annual growth rate (CAGR), from $4K to $1.13M.
- What does finance income mean?
- This metric represents the interest, dividends, or other gains earned from cash balances, short-term investments, or other financial assets held by the company. It reflects the non-operating yield generated by the firm's treasury management activities. For biopharmaceutical companies, this income helps offset a portion of the cash burn associated with ongoing research and development programs.